Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Expands Into Asia With Korean Hospital Deal

CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has entered the Asian market through a partnership with Seoul National University Hospital. A parallel deal with cloud IT company Megazone will allow the company to reach other potential customers in South Korea, Japan, and Vietnam.

Seoul National University Cancer Hospital will install the Syapse data-aggregation platform in its 28 centers across Korea, while Megazone, a major Amazon Web Services consulting partner in Asia, will provide IT support, the three entities said today. SNUH said oncologists should be able to make better treatment decisions with the help of Syapse's molecular analysis technology.

The South Korean health system is Syapse's first customer outside the US, the vendor said.

"SNUH has long been on the cutting edge in both cancer care and technology, and I’m thrilled to be partnering with them to help bring precision medicine to patients in South Korea,"  Syapse CEO Ken Tarkoff said in a statement.

"Through our precision medicine platform, we hope Seoul National University Hospital will provide a new standard for the evidence-based precision treatment of cancer," added SNUH Chief Information Officer Kyung Hwan Kim, a cardiothoracic surgeon.

San Francisco-based Syapse raised $30 million in new venture capital last fall to support such expansions.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.